CDK4 and inflammatory breast carcinoma: Fortunately, even in the time elapsed since the end of our study’s inclusion period, there have been significant advances in systemic therapy for patients with HR+ disease, including increased use of CDK4/6 inhibitors and emerging therapies from clinical trials, such as I-SPY.27,28 We hope that neoadjuvant use of some of these treatments and concomitant improvement in response among patients with IBC may facilitate more receipt of guideline-concordant surgery.